Understanding the biology of Protein Arginine Methyltransferase 5 (PRMT5), a high value therapeutic target in oncology, has long been limited by the challenge of accurately quantifying its associated metabolites. Successful PRMT5 inhibitor development requires insight into the full metabolic context, not just target expression. PRMT5 activity depends heavily on the methionine cycle, especially levels of the methyl donor S-adenosylmethionin (SAM) and the byproduct 5′-methylthioadenosine (MTA).
PRMT5-Methionine Cycle
PRMT5 catalyzes the formation of symmetric dimethylarginine (SDMA), linking arginine methylation directly to the methionine cycle using SAM as a methyl donor and the MTAP-dependent recycling of MTA.
In cancer, MTAP deletion drives MTA accumulation and elevates PRMT5 sensitivity, making SDMA a key readout for pathway activity and PRMT5 inhibitor response.
Key metabolites in the PRMT5 and methionine cycle require specialized analytical workflows due to their reactive nature and the need for precise isomer resolution. Panome Bio’s PRMT5 Metabolomics Panel is engineered to deliver this level of precision and biological context, enabling accurate, pathway-level quantification far beyond traditional single-analyte or antibody-based approaches.
PRMT5 Metabolomics Panel
Our PRMT5 assay delivers high-confidence, pathway- level data through:
- HILIC/HRMS/MS workflow that precisely distinguishes and quantifies ADMA and SDMA isomers.
- Stable isotope–labeled internal standards for reliable measurement of chemically unstable metabolites like SAM and MTA across tissue, plasma, and FFPE.
- Comprehensive coverage of the PRMT5–MTAP–methionine cycle pathway
| Panome Bio’s PRMT5 Metabolomics Panel Measures: |
|---|
| SAM |
| MTA |
| SDMA |
| ADMA |
| Methionine |
| Homocysteine (HCY) |
| S-adenosyl homocysteine (SAH) |
| Ornithine |
| Acetyl-ornithine |
| Acetyl-homoserine |
| Adenine |
| 5-methylthioribose |
| Arginine |
| Spermine |
| Serine |
| Glycine |
Designed for Translational & Clinical Impact
PRMT5 Metabolomics Panel provides the biochemical context to guide:
- Preclinical efficacy and mechanism-of-action studies
- Biomarker-driven clinical trial design
- MTAP-loss cohort evaluation and stratification
- Combination therapy development
- PRMT5/PRMT1 mechanistic studies
For PRMT5 inhibitor programs, this data sharpens tumor response differentiation, strengthens translational rationale, and reduces program risk by linking pathway activity to MTAP-related metabolic shifts.
Precise Differentiation of ADMA and SDMA
Panome Bio’s assay confidently distinguishes PRMT5’s product SDMA from PRMT1’s ADMA, providing unambiguous identification of each methylarginine.
This allows SDMA to reliably reflect PRMT5 activity, while ADMA tracks PRMT1, enabling clear interpretation of pathway selectivity, off-target effects, and inhibitor engagement.
To demonstrate the capability, Panome Bio analyzed six paired human adenocarcinoma (tumor) and adjacent normal tissue (control) samples using the PRMT5 Metabolomics Panel. This analysis highlights how our rigorous approach yields data that accurately reflects biological changes, crucial for translational research.
Tumor Methionine Cycle Shift
The PRMT5 Metabolomics Panel revealed clear metabolic dysregulation within the PRMT5-methionine cycle axis in tumor samples. Tumor Tissue consistently showed elevated levels of SAM, MTA and SAH, indicating increased methylation demand and altered methionine cycle flux.
Pioneer the Path in PRMT5 Biomarker Research:
The PRMT5 Metabolomics Panel delivers a precise, pathway-level view of PRMT5 activity, capturing SDMA and ADMA dynamics alongside key methionine cycle metabolites.
Panome Bio’s workflow reveals the complex metabolic picture of tumors, identifies MTAP-associated vulnerabilities, and uncovers critical pathway shifts that drive therapeutic sensitivity. Researchers using the PRMT5 Metabolomics Panel gain essential, high-quality data that powers smarter decision-making and accelerates next-generation PRMT5 inhibitor development.
From Metabolism to Mechanism, Profile PRMT5 Activity in Cancer with Precision
Dive into our PRMT5 data including more highlights from the case study
PRMT5 Metabolomics Panel with Panome Bio
The future of oncology research begins with a deeper understanding of tumor metabolism. Panome Bio’s validated PRMT5 Metabolomics Panel reveals the full metabolic context of PRMT5 and methionine cycle activity. We help researchers translate complex data into actionable results, identify MTAP-associated vulnerabilities, and guide the development of next-generation PRMT5 inhibitors.
Contact us to start your project.